While GSK is still expected to top the vaccine industry in 2022, rankings for other players have shifted in Evaluate's new World Preview.
Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
The EU's highest court ruled that EU national courts don't need scientific proof to consider a vaccine as defect.
Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
Florida lawmakers are urging the Army to pump the brakes on its exclusive vaccine license to Sanofi.
Scientists at the University of Maryland, hoping to fill the hepatitis vaccine void, have secured funding from the NIH to work on a new candidate.
A new U.S. study shows that Merck's Ebola vaccine rVSV-ZEBOV offers protection that can last for at least a year.
The Radboud University Medical Center in the Netherlands, the Instituto de Medicina Molecular Lisboa in Portugal, and PATH are collaborating on a human trial…